| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Clinical Cancer Genetics and Human Cancer
Genetics Programs,*
Ohio State University Comprehensive
Cancer Center, Columbus, Ohio; the Department of
Pathology,
University of Zürich,
Zürich, Switzerland; the Charles A. Dana Human Cancer Genetics
Unit,
Dana-Farber Cancer Institute, Boston,
Massachusetts; the Massachusetts Institute of
Technology,§
Boston, Massachusetts; the
Departments of Pathology and Surgery,¶
Martin-Luther-University of Halle-Wittenberg, Halle/Saale, Germany; the
Kolling Institute for Medical Research and Department of
Surgery,||
Royal North Shore Hospital, University of
Sydney, St. Leonards, New South Wales, Australia; the Department of
Pathology,**
Brigham and Women’s Hospital and
Harvard Medical School, Boston, Massachusetts; and the Cancer Research
Campaign Human Cancer Genetics Research
Group,
University of Cambridge,
Cambridge, United Kingdom
Germline mutations in PTEN (MMAC1/TEP1) are found in patients with Cowden syndrome, a familial cancer syndrome which is characterized by a high risk of breast and thyroid neoplasia. Although somatic intragenic PTEN mutations have rarely been found in benign and malignant sporadic thyroid tumors, loss of heterozygosity (LOH) has been reported in up to one fourth of follicular thyroid adenomas (FAs) and carcinomas. In this study, we examined PTEN expression in 139 sporadic nonmedullary thyroid tumors (55 FA, 27 follicular thyroid carcinomas, 35 papillary thyroid carcinomas, and 22 undifferentiated thyroid carcinomas) using immunohistochemistry and correlated this to the results of LOH studies. Normal follicular thyroid cells showed a strong to moderate nuclear or nuclear membrane signal although the cytoplasmic staining was less strong. In FAs the neoplastic nuclei had less intense PTEN staining, although the cytoplasmic PTEN-staining intensity did not differ significantly from that observed in normal follicular cells. In thyroid carcinomas as a group, nuclear PTEN immunostaining was mostly weak in comparison with normal thyroid follicular cells and FAs. The cytoplasmic staining was more intense than the nuclear staining in 35 to 49% of carcinomas, depending on the histological type. Among 81 informative tumors assessed for LOH, there seemed to be an associative trend between decreased nuclear and cytoplasmic staining and 10q23 LOH (P = 0.003, P = 0.008, respectively). These data support a role for PTEN in the pathogenesis of follicular thyroid tumors.
This article has been cited by other articles:
 |
|
 |
|
  K. Sakamoto, K. Iwasaki, H. Sugiyama, and Y. Tsuji Role of the Tumor Suppressor PTEN in Antioxidant Responsive Element-mediated Transcription and Associated Histone Modifications Mol. Biol. Cell, March 15, 2009; 20(6): 1606 - 1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Lobo, K. A. Waite, S. M. Planchon, T. Romigh, J. A. Houghton, and C. Eng ATP modulates PTEN subcellular localization in multiple cancer cell lines Hum. Mol. Genet., September 15, 2008; 17(18): 2877 - 2885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Okada, S.-W. Jang, and K. Ye Akt phosphorylation and nuclear phosphoinositide association mediate mRNA export and cell proliferation activities by ALY PNAS, June 24, 2008; 105(25): 8649 - 8654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fouladkou, T. Landry, H. Kawabe, A. Neeb, C. Lu, N. Brose, V. Stambolic, and D. Rotin The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization PNAS, June 24, 2008; 105(25): 8585 - 8590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Planchon, K. A. Waite, and C. Eng The nuclear affairs of PTEN J. Cell Sci., February 1, 2008; 121(3): 249 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Riesco-Eizaguirre and P. Santisteban New insights in thyroid follicular cell biology and its impact in thyroid cancer therapy Endocr. Relat. Cancer, December 1, 2007; 14(4): 957 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tamguney and D. Stokoe New insights into PTEN J. Cell Sci., December 1, 2007; 120(23): 4071 - 4079. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Liu, Z. Mao, T. A. LaFortune, M. M. Alonso, G. E. Gallick, J. Fueyo, and W.K. A. Yung Cell Cycle Dependent Nuclear Export of Phosphatase and Tensin Homologue Tumor Suppressor Is Regulated by the Phosphoinositide-3-Kinase Signaling Cascade Cancer Res., November 15, 2007; 67(22): 11054 - 11063. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Foukakis, A. Gusnanto, A. Y. Au, A. Hoog, W.-O. Lui, C. Larsson, G. Wallin, and J. Zedenius A PCR-based expression signature of malignancy in follicular thyroid tumors Endocr. Relat. Cancer, June 1, 2007; 14(2): 381 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Yeager, A. Klein-Szanto, S. Kimura, and A. Di Cristofano Pten Loss in the Mouse Thyroid Causes Goiter and Follicular Adenomas: Insights into Thyroid Function and Cowden Disease Pathogenesis Cancer Res., February 1, 2007; 67(3): 959 - 966. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Packer, S. Pavey, A. Parker, M. Stark, P. Johansson, B. Clarke, P. Pollock, M. Ringner, and N. Hayward Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN Carcinogenesis, September 1, 2006; 27(9): 1778 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gil, A. Andres-Pons, E. Fernandez, M. Valiente, J. Torres, J. Cervera, and R. Pulido Nuclear Localization of PTEN by a Ran-dependent Mechanism Enhances Apoptosis: Involvement of an N-Terminal Nuclear Localization Domain and Multiple Nuclear Exclusion Motifs Mol. Biol. Cell, September 1, 2006; 17(9): 4002 - 4013. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Orbo, C. E. Rise, and G. L. Mutter Regression of Latent Endometrial Precancers by Progestin Infiltrated Intrauterine Device Cancer Res., June 1, 2006; 66(11): 5613 - 5617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Garcia-Rostan, A. M. Costa, I. Pereira-Castro, G. Salvatore, R. Hernandez, M. J.A. Hermsem, A. Herrero, A. Fusco, J. Cameselle-Teijeiro, and M. Santoro Mutation of the PIK3CA Gene in Anaplastic Thyroid Cancer Cancer Res., November 15, 2005; 65(22): 10199 - 10207. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liu, S. L. Asa, and S. Ezzat 1{alpha},25-Dihydroxyvitamin D3 Targets PTEN-Dependent Fibronectin Expression to Restore Thyroid Cancer Cell Adhesiveness Mol. Endocrinol., September 1, 2005; 19(9): 2349 - 2357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Liu, X. Sheng, Z. K. Hortobagyi, Z. Mao, G. E. Gallick, and W. K. A. Yung Nuclear PTEN-Mediated Growth Suppression Is Independent of Akt Down-Regulation Mol. Cell. Biol., July 15, 2005; 25(14): 6211 - 6224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mikhail, E. Velazquez, R. Shapiro, R. Berman, A. Pavlick, L. Sorhaindo, J. Spira, C. Mir, K. S. Panageas, D. Polsky, et al. PTEN Expression in Melanoma: Relationship with Patient Survival, Bcl-2 Expression, and Proliferation Clin. Cancer Res., July 15, 2005; 11(14): 5153 - 5157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Musat, M Korbonits, B Kola, N Borboli, M R Hanson, A M Nanzer, J Grigson, S Jordan, D G Morris, M Gueorguiev, et al. Enhanced protein kinase B/Akt signalling in pituitary tumours Endocr. Relat. Cancer, June 1, 2005; 12(2): 423 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Waite, M. R. Sinden, and C. Eng Phytoestrogen exposure elevates PTEN levels Hum. Mol. Genet., June 1, 2005; 14(11): 1457 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Chung, M. E. Ginn-Pease, and C. Eng Phosphatase and Tensin Homologue Deleted on Chromosome 10 (PTEN) Has Nuclear Localization Signal-Like Sequences for Nuclear Import Mediated by Major Vault Protein Cancer Res., May 15, 2005; 65(10): 4108 - 4116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Motti, D. Califano, G. Troncone, C. De Marco, I. Migliaccio, E. Palmieri, L. Pezzullo, L. Palombini, A. Fusco, and G. Viglietto Complex Regulation of the Cyclin-Dependent Kinase Inhibitor p27kip1 in Thyroid Cancer Cells by the PI3K/AKT Pathway: Regulation of p27kip1 Expression and Localization Am. J. Pathol., March 1, 2005; 166(3): 737 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Perren, S Schmid, T Locher, P Saremaslani, C Bonvin, P U Heitz, and P Komminoth BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors Endocr. Relat. Cancer, December 1, 2004; 11(4): 855 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Lacalle, C. Gomez-Mouton, D. F. Barber, S. Jimenez-Baranda, E. Mira, C. Martinez-A., A. C. Carrera, and S. Manes PTEN regulates motility but not directionality during leukocyte chemotaxis J. Cell Sci., December 1, 2004; 117(25): 6207 - 6215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Tell, A. Pines, F. Arturi, L. Cesaratto, E. Adamson, C. Puppin, I. Presta, D. Russo, S. Filetti, and G. Damante Control of Phosphatase and Tensin Homolog (PTEN) Gene Expression in Normal and Neoplastic Thyroid Cells Endocrinology, October 1, 2004; 145(10): 4660 - 4666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Goel, C. N. Arnold, D. Niedzwiecki, J. M. Carethers, J. M. Dowell, L. Wasserman, C. Compton, R. J. Mayer, M. M. Bertagnolli, and C. R. Boland Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers Cancer Res., May 1, 2004; 64(9): 3014 - 3021. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Musatov, J. Roberts, A. I. Brooks, J. Pena, S. Betchen, D. W. Pfaff, and M. G. Kaplitt Inhibition of neuronal phenotype by PTEN in PC12 cells PNAS, March 9, 2004; 101(10): 3627 - 3631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Orchiston, D. Bennett, N. R. Leslie, R. G. Clarke, L. Winward, C. P. Downes, and S. T. Safrany PTEN M-CBR3, a Versatile and Selective Regulator of Inositol 1,3,4,5,6-Pentakisphosphate (Ins(1,3,4,5,6)P5): EVIDENCE FOR Ins(1,3,4,5,6)P5 AS A PROLIFERATIVE SIGNAL J. Biol. Chem., January 9, 2004; 279(2): 1116 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C.I. Goberdhan and C. Wilson PTEN: tumour suppressor, multifunctional growth regulator and more Hum. Mol. Genet., October 15, 2003; 12(90002): R239 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Deleris, D. Bacqueville, S. Gayral, L. Carrez, J.-P. Salles, B. Perret, and M. Breton-Douillon SHIP-2 and PTEN Are Expressed and Active in Vascular Smooth Muscle Cell Nuclei, but Only SHIP-2 Is Associated with Nuclear Speckles J. Biol. Chem., October 3, 2003; 278(40): 38884 - 38891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Choe, S. Horvath, T. F. Cloughesy, K. Crosby, D. Seligson, A. Palotie, L. Inge, B. L. Smith, C. L. Sawyers, and P. S. Mischel Analysis of the Phosphatidylinositol 3'-Kinase Signaling Pathway in Glioblastoma Patients in Vivo Cancer Res., June 1, 2003; 63(11): 2742 - 2746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Aldred, M. E. Ginn-Pease, C. D. Morrison, A. P. Popkie, O. Gimm, C. Hoang-Vu, U. Krause, H. Dralle, S. M. Jhiang, C. Plass, et al. Caveolin-1 and Caveolin-2,Together with Three Bone Morphogenetic Protein-related Genes, May Encode Novel Tumor Suppressors Down-Regulated in Sporadic Follicular Thyroid Carcinogenesis Cancer Res., June 1, 2003; 63(11): 2864 - 2871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Halvorsen, S. A. Haukaas, and L. A. Akslen Combined Loss of PTEN and p27 Expression Is Associated with Tumor Cell Proliferation by Ki-67 and Increased Risk of Recurrent Disease in Localized Prostate Cancer Clin. Cancer Res., April 1, 2003; 9(4): 1474 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Waite and C. Eng BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels Hum. Mol. Genet., March 15, 2003; 12(6): 679 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Ginn-Pease and C. Eng Increased Nuclear Phosphatase and Tensin Homologue Deleted on Chromosome 10 Is Associated with G0-G1 in MCF-7 Cells Cancer Res., January 15, 2003; 63(2): 282 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yu, N. Fotouhi-Ardakani, L. Wu, M. Maoui, S. Wang, D. Banville, and S.-H. Shen PTEN Associates with the Vault Particles in HeLa Cells J. Biol. Chem., October 18, 2002; 277(43): 40247 - 40252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-P. Zhou, A. Loukola, R. Salovaara, M. Nystrom-Lahti, P. Peltomaki, A. de la Chapelle, L. A. Aaltonen, and C. Eng PTEN Mutational Spectra, Expression Levels, and Subcellular Localization in Microsatellite Stable and Unstable Colorectal Cancers Am. J. Pathol., August 1, 2002; 161(2): 439 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. B. Knobbe, A. Merlo, and G. Reifenberger Pten signaling in gliomas Neuro Oncology, July 1, 2002; 4(3): 196 - 211. [Abstract] [PDF]
|
|
|
|
|
|
M. Fernandez and C. Eng The Expanding Role of PTEN in Neoplasia: A Molecule for All Seasons? : Commentary re: M. A. Davies, et al., Adenoviral-mediated Expression of MMAC/PTEN Inhibits Proliferation and Metastasis of Human Prostate Cancer Cells. Clin. Cancer Res., 8: 1904-1914, 2002. Clin. Cancer Res., June 1, 2002; 8(6): 1695 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Liu, S. L. Asa, I. G. Fantus, P. G. Walfish, and S. Ezzat Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways Am. J. Pathol., February 1, 2002; 160(2): 511 - 519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Mutter PTEN, a Protean Tumor Suppressor Am. J. Pathol., June 1, 2001; 158(6): 1895 - 1898. [Full Text] [PDF]
|
|
|
|
|
|
K. Kurose, X.-P. Zhou, T. Araki, S. A. Cannistra, E. R. Maher, and C. Eng Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas Am. J. Pathol., June 1, 2001; 158(6): 2097 - 2106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-P. Weng, O. Gimm, J. B. Kum, W. M. Smith, X.-P. Zhou, D. Wynford-Thomas, G. Leone, and C. Eng Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death Hum. Mol. Genet., February 1, 2001; 10(3): 251 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gimm, M. Armanios, H. Dziema, H. P. H. Neumann, and C. Eng Somatic and Occult Germ-line Mutations in SDHD, a Mitochondrial Complex II Gene, in Nonfamilial Pheochromocytoma Cancer Res., December 1, 2000; 60(24): 6822 - 6825. [Abstract] [Full Text]
|
|
|
|
|
|
A. Perren, P. Komminoth, P. Saremaslani, C. Matter, S. Feurer, J. A. Lees, P. U. Heitz, and C. Eng Mutation and Expression Analyses Reveal Differential Subcellular Compartmentalization of PTEN in Endocrine Pancreatic Tumors Compared to Normal Islet Cells Am. J. Pathol., October 1, 2000; 157(4): 1097 - 1103. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-P. Zhou, O. Gimm, H. Hampel, T. Niemann, M. J. Walker, and C. Eng Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation Am. J. Pathol., October 1, 2000; 157(4): 1123 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gimm, T. Attie-Bitach, J. A. Lees, M. Vekemans, and C. Eng Expression of the PTEN tumour suppressor protein during human development Hum. Mol. Genet., July 1, 2000; 9(11): 1633 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Torres and R. Pulido The Tumor Suppressor PTEN Is Phosphorylated by the Protein Kinase CK2 at Its C Terminus. IMPLICATIONS FOR PTEN STABILITY TO PROTEASOME-MEDIATED DEGRADATION J. Biol. Chem., January 5, 2001; 276(2): 993 - 998. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
